Q-omics provides the consensus-scored GXYLT1P7 profile across patient tissues and cancer cell-line models. GXYLT1P7 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GXYLT1P7 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, GXYLT1P7 RNA expression shows 6,298 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, and STAD as cancer lineages where GXYLT1P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GXYLT1P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GXYLT1P7 survival associations across molecular data types. GXYLT1P7 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GXYLT1P7 RNA expression–survival associations across cancer types. High GXYLT1P7 expression shows unfavorable associations in LIHC, TGCT, KIRP, THYM, BLCA and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GXYLT1P7 RNA expression.
This table summarizes GXYLT1P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GXYLT1P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GXYLT1P7 shows lower tumor expression in STAD, BRCA, KIRC and KICH and higher tumor expression in LUAD. The STAD box plot shows higher GXYLT1P7 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .015).
This table shows molecular features associated with GXYLT1P7 in patient tissues and cancer cell lines. In patient samples, GXYLT1P7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
